Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Maat Pharma SA
PAR:MAAT
|
FR |
|
A
|
Able Global Bhd
KLSE:ABLEGLOB
|
MY |
|
Suvo Strategic Minerals Ltd
ASX:SUV
|
AU |
|
M
|
Maison Solutions Inc
NASDAQ:MSS
|
US |
|
Fu Yu Corporation Ltd
SGX:F13
|
SG |
|
Caisse regionale de Credit Agricole Mutuel d'Ille-et-Vilaine
PAR:CIV
|
FR |
|
Financiere Moncey SA
PAR:FMONC
|
FR |
|
PepsiCo Inc
NASDAQ:PEP
|
US |
|
M
|
Motor Oil Hellas Corinth Refineries SA
ATHEX:MOH
|
GR |
|
Manitex International Inc
NASDAQ:MNTX
|
US |
|
P
|
Palram Industries 1990 Ltd
TASE:PLRM
|
IL |
|
Ted Baker PLC
LSE:TED
|
UK |
|
Dave & Buster's Entertainment Inc
NASDAQ:PLAY
|
US |
|
Amedisys Inc
NASDAQ:AMED
|
US |
|
Cherry Hill Mortgage Investment Corp
NYSE:CHMI
|
US |
|
Avast PLC
LSE:AVST
|
UK |
Wall Street
Price Targets
MAAT Price Targets Summary
Maat Pharma SA
According to Wall Street analysts, the average 1-year price target for MAAT is 17.27 EUR with a low forecast of 13.13 EUR and a high forecast of 22.05 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is MAAT's stock price target?
Price Target
17.27
EUR
According to Wall Street analysts, the average 1-year price target for MAAT is 17.27 EUR with a low forecast of 13.13 EUR and a high forecast of 22.05 EUR.
What is Maat Pharma SA's Revenue forecast?
Projected CAGR
134%
The compound annual growth rate of Maat Pharma SA's revenue for the next 4 years is 134%.